## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($92.96)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 2, Bearish: 1)

**1. Revvity (NYSE: RVTY) unveils Signals Xynthetica AI MaaS for discovery workflows**
- Source: Stock Titan | 20251216T130254 | Bullish | Relevance: 100%
- Revvity, Inc. (NYSE: RVTY) has introduced its new Signals Xyntheticaâ„¢ Models-as-a-Service (MaaS) AI offering within the Revvity Signals platform. This AI-augmented design platform aims to integrate in-silico generation, predictive modeling, and experimental validation to accelerate molecular and materials discovery. The platform addresses the gap between powerful AI algorithms and their real-world impact by seamlessly connecting AI predictions with experimental data in scientific workflows.

**2. Barclays Adjusts Price Target on Revvity to $115 From $105, Maintains Overweight Rating**
- Source: marketscreener.com | 20251215T150842 | Somewhat-Bullish | Relevance: 100%
- Barclays has increased its price target for Revvity to $115 from $105, while reiterating an Overweight rating on the stock. This adjustment comes amidst other analyst activities, including Wells Fargo also raising its price target and BofA Securities downgrading the stock. Revvity specializes in medical diagnosis and analytical equipment, with significant operations in the US and China.

**3. Revvity stock rating downgraded to Neutral by BofA Securities**
- Source: Investing.com | 20251215T130845 | Bearish | Relevance: 100%
- BofA Securities downgraded Revvity Inc (NYSE:RVTY) from Buy to Neutral, citing limited upside potential due to challenges in its China diagnostics business and a modest 2026 outlook. Despite the downgrade, the new price target of $110.00 still suggests a 9.5% upside from current levels. The firm recommends investors explore other opportunities in the tools sector for now, despite Revvity exceeding Q3 EPS expectations and acquiring ACD/Labs.

**4. Revvity stock rating downgraded to Neutral by BofA Securities**
- Source: Investing.com South Africa | 20251215T190854 | Somewhat-Bearish | Relevance: 100%
- BofA Securities downgraded Revvity Inc (NYSE:RVTY) from Buy to Neutral, citing limited upside potential despite a raised price target to $110.00. The firm highlighted Revvity's high P/E ratio, ongoing challenges in its China diagnostics business, and a conservative 2026 outlook as reasons for the downgrade. This comes as Revvity recently announced exceeding Q3 2025 EPS expectations and plans to acquire ACD/Labs.

**5. Revvity (NYSE:RVTY) Lowered to "Neutral" Rating by Bank of America**
- Source: MarketBeat | 20251215T154144 | Somewhat-Bearish | Relevance: 100%
- Bank of America has downgraded Revvity (NYSE:RVTY) from a "buy" to a "neutral" rating, setting a $110 price target, which implies an 11.7% upside. Despite this, the consensus analyst rating remains "Hold" with an average price target of $115.25. The company recently approved a $1.0 billion share buyback program and issued FY2025 EPS guidance, trading near $98.45 with a P/E of approximately 49.3.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $115 | $105 | +10% |
| 2025-12-15 | Wells Fargo | $107 | $102 | +5% |
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Elevated short interest (9.1%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.66 indicates undervaluation relative to growth. Forward P/E 18.7x stretched relative to 8% growth. Analyst sentiment positive (2 raises, avg +7%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.5B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 9.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.66 |
| Forward P/E | 18.7 |
| Current P/E | 20.2 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -4.4% to -0.7% (+3.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.7pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.04x) but short-term weakness (below SMA20). RSI neutral at 50. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.68% (CS: 20) | Neutral |
| RSI_14 | 50.3 | Neutral |
| MACD Histogram | -0.41 | Bearish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 1.032x | Above |
| vs SMA200 | 1.040x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $99.08
- **Stop Loss:** $92.96 (6.2% risk)
- **Target:** $105.20 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 196
- **Position Value:** $19,419.68
- **Portfolio %:** 19.42%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*